MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances

ROCKVILLE, Md., July 15 (PRNewswire) — MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health NIH has awarded the company three new grants representing total funding of $9.8 million. These grants will help MacroGenics further advance its Dual-Affinity Re-Targeting DART, or bispecific antibody scaffold platform, as well as its portfolio of infectious disease product candidates. The first of three recently awarded NIH grants will fund preclinical IND-enabling activities related to MacroGenics’ Inflammation DART. This DART specifically targets B lymphocytes with the potential to treat a broad range of autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis and other disorders.

via MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances… — ROCKVILLE, Md., July 15 /PRNewswire/ —.

Be the first to comment

Leave a Reply

Your email address will not be published.


*